iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
Key Highlights
- ➤$4.5 million acquisition adds AI tools for protein discovery and disease trend monitoring
- ➤$2.5 million stock consideration issued as 2,907,977 shares to Foldlab
- ➤$750,000 cash paid at closing; up to $1.25 million remains milestone-based
- ➤iSpecimen acquired full software, model weights, data rights, and related intellectual property
- ➤Shares carry five-year trading restriction, lock-up, and voting rights agreement
Expert Statements
Shahin Behroyan, Chief Executive Officer of iSpecimen
“This acquisition expands iSpecimen's role in the research and discovery process by bringing together our biospecimen network and AI tools.”
Shahin Behroyan, Chief Executive Officer of iSpecimen
“These capabilities have the potential to help researchers identify promising protein targets and better understand disease trends.”
Shahin Behroyan, Chief Executive Officer of iSpecimen
“For iSpecimen, they create opportunities to deepen customer relationships, reach new markets and develop complementary software and analytics revenue streams.”
New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace
Woburn, Massachusetts--(Newsfile Corp. - November 5, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen providers, today announced that it completed, on November 2, 2026, the acquisition of two artificial intelligence products from Foldlab AI Ltd. ("Foldlab"), a British Columbia company: an AI agent that identifies disease-associated proteins and an AI model that predicts and monitors disease trends.
Get started
Create a free account to read the full story.